Serina Therapeutics, Inc. (SER) — 10-Q Filings
All 10-Q filings from Serina Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Serina's Cash Burn Accelerates Amid Soaring R&D, Going Concern Doubt Looms
— Nov 13, 2025 Risk: high
Serina Therapeutics, Inc. (SER) reported a significant net loss of $15.8 million for the nine months ended September 30, 2025, a substantial increase from the $ -
Serina Therapeutics' Losses Widen Amid Zero Revenue
— Aug 11, 2025 Risk: high
Serina Therapeutics, Inc. reported no grant revenue for the three and six months ended June 30, 2025, a significant decrease from $1,000 in grant revenue for bo -
Serina Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Serina Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as AgeX Therapeutics, Inc., reported financial result -
Serina Therapeutics Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
Serina Therapeutics, Inc. filed its Q3 2024 10-Q report on November 12, 2024, for the period ending September 30, 2024. The company, formerly known as AgeX Ther -
Serina Therapeutics Files Q2 2024 10-Q
— Aug 9, 2024 Risk: medium
Serina Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as AgeX Therapeutics, Inc., reported its financial res
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX